Please see summary below from Novartis Gene Therapies on the OAV301 program for familial ALS caused by the SOD1 mutation: Novartis Gene Therapies (formerly AveXis) deeply appreciates the collaboration and support of the amyotrophic lateral sclerosis (ALS) community. Our ALS …
BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study
Today was a tough call for the ALS community, but not entirely disheartening. BrainStorm released the topline results this morning (November 17) from its Phase 3 trial for NurOwn® showing it did not meet statistical significance in its primary efficacy …
November 2020 Events eNews
Go All in for ALS this Friday Night A 3 day, 2 night stay at a charming cottage nestled in the Indiana Dunes could be yours! This magical getaway is just one of the silent auction prizes offered at our …
November 2020 Foundation eNews
Empowering through ALS Education We are excited to launch our new online learning series aimed at empowering our ALS community through the latest information and insights. Educational webinars and interactive Q&A’s covering a diverse array of topics, from telemedicine to …
Amylyx Publishes CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS
We are excited to share some promising data regarding the CENTAUR trial evaluating AMX0035 in people with ALS on overall survival analysis, published today (October 16, 2020) in the neuromuscular disease journal Muscle & Nerve. The survival analysis followed each …
October 2020 Events eNews
Betting on Your Support Are you feeling lucky? Join us for the Virtual All in for ALS Casino Night, hosted by our Young ProfessionALS Group, on Friday, Nov. 13 at 7pm. The virtual event will feature all of the exciting …
October 2020 Foundation eNews
Join our 10th Annual Les Turner Symposium on ALS – Monday, November 9 Registration is now open for our 10th Annual Symposium, hosted by our own Les Turner ALS Center at Northwestern Medicine. This year’s event will be held virtually on …
Advocacy Announcement: ALS Disability Insurance Access Act
Foundation Blog: Advocacy The Les Turner ALS Foundation has joined with several other national ALS patient advocacy organizations (ALS Association, I AM ALS, Muscular Dystrophy Association and Team Gleason) in a letter to U.S. House of Representatives’ leadership requesting that …
Data from Amylyx’s CENTAUR trial shows promise in slowing ALS progression
We are very pleased to share promising data published this week in the New England Journal of Medicine from the recent CENTAUR trial, conducted by Amylyx Pharmaceuticals, showing that AMX0035, the combination drug of sodium phenylbutyrate–taurursodiol, can slow functional decline …
